TransMedics Group, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Waleed H. Hassanein
- Full Time Employees
- 898
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 200 Minuteman Road Andover MA United States of America 01810
- IPO Date
- May 2, 2019
- CIK
- 0001756262
- Website
- transmedics.com
- Similar Companies
- Business
- TransMedics Group, Inc. develops and commercializes medical technologies that transform organ transplant therapy for patients with end-stage heart, lung and liver failure; the company offers the Organ Care System (OCS), a portable extracorporeal warm perfusion, optimization and monitoring platform that replicates near-physiologic conditions for donor organs outside the body, with specific systems for hearts, lungs and livers; it also provides the National OCS Program (NOP), an end-to-end outsourced solution encompassing organ procurement, OCS perfusion management, transplant logistics and aviation transportation services, supported by trained surgeons, clinical specialists and coordinators. TransMedics operates primarily in the United States, with international reach, and targets transplant centers serving patients with end-stage organ failure. Founded in 1998 and headquartered in Andover, Massachusetts, the company continues to expand its capabilities through recent aircraft fleet acquisitions, including a fixed-wing plane purchased in January 2025 for $14.1 million from RCS Leasing, LLC, bringing its total to 20 aircraft as part of the NOP to enhance donor organ transportation.
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Chuck Royce's Second Quarter 2026 13F: Catalyst Pharmaceuticals Reduction Leads Portfolio Shifts
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
TransMedics Group Inc (TMDX) Stock Up 4.9% and Still Undervalued -- GF Score: 70/100
TransMedics Group (NASDAQ:TMDX) Shares Gap Down After Earnings Miss
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract
Why TransMedics Stock Is Sinking Today
TransMedics Group, Inc. (TMDX) Q2 2026 Earnings Call Transcript
TransMedics Group Q2 Earnings Call Highlights
TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say
TransMedics (TMDX) Q2 Earnings Lag Estimates
TransMedics Reports Second Quarter 2026 Financial Results
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. -- TMDX
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference